ArticleClinical Medicine Insights. Oncology2024

First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.

Guiyuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.